Free Trial

Journey Strategic Wealth LLC Grows Position in Danaher Corporation (NYSE:DHR)

Danaher logo with Medical background

Journey Strategic Wealth LLC increased its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 41.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,199 shares of the conglomerate's stock after buying an additional 1,236 shares during the quarter. Journey Strategic Wealth LLC's holdings in Danaher were worth $861,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Bank Pictet & Cie Europe AG grew its stake in shares of Danaher by 22.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after buying an additional 35,730 shares in the last quarter. Congress Wealth Management LLC DE boosted its holdings in Danaher by 6.1% during the 4th quarter. Congress Wealth Management LLC DE now owns 12,749 shares of the conglomerate's stock valued at $2,927,000 after acquiring an additional 736 shares during the period. Modern Wealth Management LLC boosted its holdings in Danaher by 30.5% during the 4th quarter. Modern Wealth Management LLC now owns 1,087 shares of the conglomerate's stock valued at $250,000 after acquiring an additional 254 shares during the period. Financial Engines Advisors L.L.C. boosted its holdings in Danaher by 19.8% during the 4th quarter. Financial Engines Advisors L.L.C. now owns 1,137 shares of the conglomerate's stock valued at $261,000 after acquiring an additional 188 shares during the period. Finally, Korea Investment CORP boosted its holdings in Danaher by 0.8% during the 4th quarter. Korea Investment CORP now owns 500,750 shares of the conglomerate's stock valued at $114,947,000 after acquiring an additional 3,913 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

Danaher stock traded up $2.79 during mid-day trading on Friday, reaching $205.60. 5,355,676 shares of the company were exchanged, compared to its average volume of 3,965,185. The firm's 50-day simple moving average is $196.38 and its two-hundred day simple moving average is $203.92. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70. The firm has a market cap of $147.22 billion, a PE ratio of 43.74, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.05 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the business posted $1.72 EPS. The company's revenue was up 3.4% on a year-over-year basis. Equities analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. Danaher's dividend payout ratio is currently 27.23%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft lowered their target price on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday. Argus lowered their target price on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Finally, Robert W. Baird boosted their target price on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Read Our Latest Stock Analysis on Danaher

Insider Activity at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at $3,005,442. This trade represents a 51.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines